^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

Published date:
09/16/2021
Excerpt:
This study was conducted on 224 ER-positive breast cancer patients...group 1 was tamoxifen sensitive and groups 2 and 3 were tamoxifen resistant...SOX2 and AGR2 biomarkers expression and serum AGR2 level were significantly higher in groups 2 and 3 in comparison to group 1...
DOI:
https://doi.org/10.1155/2021/9947540